CD4:CD8 Ratio and Non-AIDS Defining Events in Virally Suppressed HIV Infected Patients: Need to Look Beyond CD4+ T-Cell Counts
DOI:
https://doi.org/10.17140/HARTOJ-2-e005Abstract
Antiretroviral therapy has led to improvement in life-expectancy through viral suppression and improved immune status. This brings in the concern about the non-AIDS defining illnesses which are mostly age associated such as cardiovascular disease, stroke, renal disease, liver disease, neurocognitive disorders, and non-AIDS malignancies. These are reported to be present at comparatively younger ages in HIV-infected patients.
References
Mussini C, Lorenzini P, Cozzi-Lepri A, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral ther-apy: an observational cohort study. The Lancet HIV. 2015; 2(3): e98 - e106. doi: 10.1016/s2352-3018(15)00006-5
Serrano-Villar S, Pe´ rez-Elıas MJ, Dronda F, et al. Increased risk of serious non-AIDS-related events in HIV-infected sub-jects on antiretroviral therapy associated with a low CD4/CD8 ratio. PLOS ONE. 2014; 9(1): e85798. doi: 10.1371/journal. pone.0085798
Deeks SG, Tracy R, Douek DC. Systemic Effects of Inflam-mation on Health during Chronic HIV Infection. Immunity. 2013; 39: 633-645. doi: 10.1016/j.immuni.2013.10.001
Guaraldi G, Orlando G, Zona S, et al. Premature age related co-morbidities among HIV infected persons compared with general population. Clin Infect Dis. 2011; 53: 1120-1126. doi: 10.1093/cid/cir627
Seaberg EC, Munoz A, Lu M, et al. Association between high-ly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005; 19: 953-960.
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV in-fection as a chronic disease. The Lancet. 2013. doi: 10.1016/ S0140-6736(13)61809-7
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006; 355: 2283-2296. doi: 10.1056/nejmoa062360
Stephan C, Hill A, Xi N, van Delft Y, Moecklinghoff C. Re-search letter. Is monitoring for CD4 counts still needed for the management of patients with long-term HIV RNA suppression? J Acquir Immune Defic Syndr. 2012; 61: e73-e75. doi: 10.1097/ QAI.0b013e3182737254
Lucero T, Torres B, Leon A, et al. Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm3. AIDS Res Hum Retroviruses. 2013; 29: 993-999. doi: 10.1089/aid.2012.0367
Wikby A, Johansson B, Ferguson F, Olsson J. Age related changes in immune parameters ina very old population of Swed-ish peoplw: a longitudinal study. Exp Gerontol. 1994; 29: 531- 541. doi: 10.1016/0531-5565(94)90036-1
Wikby A, Maxson P, Olsson J, Johansson B, Ferguson F. Changes in CD8 and Cd4 lymphocytes subsets, T cell prolifera-tion responses and non-survival in the very old: the Swedish lon-gitudinal OCTO-immune study. Mech Ageing dev. 1998; 102: 187-198. doi: 10.1016/S0047-6374(97)00151-6
Serrano-Villar S, Saiz T, Sulggi AL, et al. HIV infected indi-viduals with low CD4/CD8 ratio despie effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation and increased risk of Non-AIDS morbidity and mor-tality. PLoS Pathog. 2014; 10: e1004078. doi: 10.1371/journal. ppat.1004078
Serrano-Villar S, Gutie`rrez C, Vallejo A, et al. The CD4/ CD8 ratio in HIV infected subjects is independently associated with T cell activation despite long term viral suppression. J In-fec. 2013; 66: 57-66. doi: 10.1016/j.jinf.2012.09.013
Sainz T, Serrano-Villar S, Diaz L, et al. The Cd4/Cd8 ratio as a marker T cell activation, senescence and activation/exhaustion in treated HIV- infected childrena dn young adults. AIDS. 2013; 27: 1513-1516. doi: 10.1097/QAD.0b013e32835faa72
Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coag-ulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5: e203. doi: 10.1371/journal.pmed.0050203
Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010; 55(2): 262-270. doi: 10.1097/ QAI.0b013e3181e9be6b
Serrano-Villar S, Moreno S, Fuentes-Ferrer M, et al. The CD4/CD8 ratio is associated with markers of age associated diseases in virally supressed HIV infected patients with immu-nological recovery. HIV Med. 2014; 15: 40-49. doi: 10.1111/ hiv.12081
Alimonti JB, Ball TB, Fowke KR. Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus in-fection and AIDS. J Gen Virol. 2003; 84(7): 1649-1661. doi: 10.1099/vir.0.19110-0
Mark Mascolini. Low CD4/CD8 Ratio Predicts non-AIDS Illness in Large Italian Cohort. Conference on Retroviruses and Opportunistic Infections. 2014.
Leung V, Gillis J, Rabound J, et al. Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy. PLoS One. 2013; 8: e77665. doi: 10.1371/journal.pone.0077665
Morre M, Beq S. Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol. 2012; (1): 55-68. doi: 10.1007/ s11523-012-0210-4
Tenorio AR, Chan ES, Bosch RJ, et al. Rifaximin has a mar-ginal impact on microbial translocation, T cell activation and inflammation in HIV-positive immune non-responders to anti-retroviral therapy - ACTG A5286. J Infect Dis. 2015; 211(5): 780-90. doi: 10.1093/infdis/jiu515
Zeidan J, Lee G, Lalezari J, et al. Host Immune Environ-ment Significantly Impact the Level of CD4 Reconstitution and the Effects on Latent Reservoir in HIV Subjects Receiving ZFN CCR5 Modified CD4 T cells (SB-728-T). 53rd Interscience Con-ference on Antimicrobial Agents and Chemotherapy (ICAAC); 2013: Denver CO. Levin: Conference Reports for National AIDS Treatment Advocacy Project (NATAP); Website: http://aidsinfo. nih.gov/drugs/532/sb-728-t/0/patient. 2013; Accessed 2015.
Fauce SR, Jamieson BD, Chin AC, et al. Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J Immunol. 2008; 181: 7400-7406. doi: 10.4049/jimmunol.181.10.7400
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in HIV/AIDS Research and Treatment (HRT) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
